Testing population-based performance measures identifies gaps in juvenile idiopathic arthritis (JIA) care
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1472-6963
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Testing population-based performance measures identifies gaps in juvenile idiopathic arthritis (JIA) care ; volume:19 ; number:1 ; day:14 ; month:8 ; year:2019 ; pages:1-7 ; date:12.2019
BMC health services research ; 19, Heft 1 (14.8.2019), 1-7, 12.2019
- Creator
-
Barber, Claire E.H
Lix, Lisa M.
Lacaille, Diane
Marshall, Deborah A.
Kroeker, Kristine
Benseler, Susanne
Twilt, Marinka
Schmeling, Heinrike
Barnabe, Cheryl
Hazlewood, Glen S.
Bykerk, Vivian
Homik, Joanne
Thorne, J. Carter
Burt, Jennifer
Mosher, Dianne
Katz, Steven
Shiff, Natalie J.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12913-019-4379-4
- URN
-
urn:nbn:de:101:1-2020010103242374990044
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Barber, Claire E.H
- Lix, Lisa M.
- Lacaille, Diane
- Marshall, Deborah A.
- Kroeker, Kristine
- Benseler, Susanne
- Twilt, Marinka
- Schmeling, Heinrike
- Barnabe, Cheryl
- Hazlewood, Glen S.
- Bykerk, Vivian
- Homik, Joanne
- Thorne, J. Carter
- Burt, Jennifer
- Mosher, Dianne
- Katz, Steven
- Shiff, Natalie J.
- SpringerLink (Online service)
Other Objects (12)
Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
How do parents of children with juvenile idiopathic arthritis (JIA) perceive their therapies?
The successes and challenges of harmonising juvenile idiopathic arthritis (JIA) datasets to create a large-scale JIA data resource
4.4 Different phenotype of anaemia in systemic juvenile idiopathic arthritis (s-JIA) compared to anaemia in other subtypes of JIA
PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
Medication therapy patients with juvenile idiopathic arthritis (JIA), who needed joint replacement in adult life
A meta-analysis to estimate the “real” placebo effect in juvenile idiopathic arthritis (JIA) trials
Application of the Yamaguchi criteria for classification of “suspected” systemic juvenile idiopathic arthritis (sJIA)
Network analysis identifies protein clusters of functional importance in juvenile idiopathic arthritis
Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA)
Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan
Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA)
Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
How do parents of children with juvenile idiopathic arthritis (JIA) perceive their therapies?
The successes and challenges of harmonising juvenile idiopathic arthritis (JIA) datasets to create a large-scale JIA data resource
4.4 Different phenotype of anaemia in systemic juvenile idiopathic arthritis (s-JIA) compared to anaemia in other subtypes of JIA
PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
Medication therapy patients with juvenile idiopathic arthritis (JIA), who needed joint replacement in adult life
A meta-analysis to estimate the “real” placebo effect in juvenile idiopathic arthritis (JIA) trials
Application of the Yamaguchi criteria for classification of “suspected” systemic juvenile idiopathic arthritis (sJIA)
Network analysis identifies protein clusters of functional importance in juvenile idiopathic arthritis
Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA)
Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan
Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA)
Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
How do parents of children with juvenile idiopathic arthritis (JIA) perceive their therapies?
The successes and challenges of harmonising juvenile idiopathic arthritis (JIA) datasets to create a large-scale JIA data resource
4.4 Different phenotype of anaemia in systemic juvenile idiopathic arthritis (s-JIA) compared to anaemia in other subtypes of JIA
PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
Medication therapy patients with juvenile idiopathic arthritis (JIA), who needed joint replacement in adult life
A meta-analysis to estimate the “real” placebo effect in juvenile idiopathic arthritis (JIA) trials
Application of the Yamaguchi criteria for classification of “suspected” systemic juvenile idiopathic arthritis (sJIA)
Network analysis identifies protein clusters of functional importance in juvenile idiopathic arthritis
Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA)
Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan